August 2026 Research Update

This month added a clearer picture that canakinumab (an IL-1 blocking medicine) often brings inflammation down quickly in children with colchicine-resistant FMF, but adjusting how often it is given does not work the same way for everyone. When patients were grouped by whether they stayed on a stable schedule, successfully extended the interval, or could not extend it, remission was most common in the stable and successful-extension groups. The group that could not extend the interval had ongoing attacks, showing that dose spacing can be challenging for some patients even when early inflammation improves. [1]

Inflammation measured by CRP (a blood marker of inflammation) fell rapidly after starting canakinumab and then leveled off after about 3 months. Attack rates also dropped after treatment began, but the chance of complete remission differed across the interval groups, with the lowest remission rate in the unsuccessful-extension group. One clinical feature stood out: arthritis at disease onset was reported as a predictor of being able to extend the dosing interval. [1]

For families already using canakinumab for colchicine-resistant FMF, these results add practical context about what has been observed when clinicians try to lengthen the time between doses in real-world pediatric care. It suggests that blood inflammation may improve early, while day-to-day control (attacks and remission) can still differ depending on the dosing interval strategy and the child. This does not prove one schedule is best, but it helps clarify that some children may be able to space doses successfully while others may not, and that early arthritis might be a clue worth studying further. [1]

This month, several human studies reinforced that FMF is not one single pattern, even when genetics are known. People with certain MEFV variants had different ages of onset and symptom mixes, and some children who carried one MEFV variant were first labeled with other inflammatory conditions before later meeting criteria for FMF during follow-up. Another large cohort showed FMF can also be present as an additional inflammatory condition in people diagnosed with Behcet's disease. [2] [3] [4]

In a German adult FMF registry, the M694V variant was common, and people with two copies (homozygous) tended to have an earlier start of symptoms and more joint pain or arthritis than other genetic groups. Amyloidosis was reported in one patient in this registry. The authors noted that subgroup findings need confirmation in other cohorts, but the overall message is that genotype can relate to how FMF looks and when it starts. [2]

In a single-center pediatric cohort of children carrying a heterozygous MEFV variant, FMF was the most common final diagnosis, but there was also a wide mix of other inflammatory diagnoses and a group of asymptomatic carriers. Importantly, among children first diagnosed with a different inflammatory condition, nearly a third later developed FMF during follow-up, showing that the clinical picture can evolve over time in carriers. The report also described that colchicine was started for typical FMF attacks and sometimes for selected reasons in other inflammatory diseases. [3]

Looking beyond FMF-only populations, a multicenter cohort of people with Behcet's disease found that a subgroup also had other inflammatory conditions, including FMF. Those with an added inflammatory diagnosis were more likely to have used anti-TNF biologic therapy, and they tended to be older with longer Behcet's duration. This supports the idea that inflammatory diseases can overlap, although the study was not focused on FMF outcomes specifically. [4]

For patients and caregivers, these studies mainly add context about variability: genetics can line up with differences in symptom patterns, and having one MEFV variant does not always predict a single clear diagnosis early on. The pediatric follow-up findings help clarify why some families experience changing labels over time before FMF becomes clearer. The Behcet's study adds awareness that FMF can be one of several inflammatory conditions in the same person, but it does not explain why that overlap happens or what it means for an individual patient's future course. [2] [3] [4]

This month, several studies focused on living with FMF and how it is measured, with a pattern of useful signals but limited proof that any single marker or lifestyle factor explains day-to-day severity. A biomarker comparison suggested CRP alone may be enough to track acute inflammation in FMF in that setting, while another study described a newer blood marker that rose during attacks but did not match disease severity scores. Separate observational studies reported higher sleep disturbance and depressive symptoms in pediatric FMF compared with controls, and examined diet patterns without finding a clear link to attack frequency or overall severity. [5] [6] [7] [8]

In a prospective comparison of inflammatory markers across several conditions, CRP and serum amyloid A (SAA) tended to move together, and the authors concluded that CRP was adequate for evaluating acute inflammation in FMF. In this study, adding SAA did not improve early detection of "silent" (subclinical) inflammation during attack-free periods. This helps clarify what was seen in one clinical setting, but it did not address long-term complications. [5]

A pediatric study measuring Phoenixin-14 (PNX-14), a proposed neuro-immune marker, found higher levels during attacks in both FMF and PFAPA, and higher levels even in attack-free periods compared with healthy children. PNX-14 showed a small positive correlation with CRP, but it did not relate to other common inflammation markers or to a disease severity score. This keeps PNX-14 in the category of a possible research marker rather than a clear tool for judging severity. [6]

In a pediatric case-control study, children and teens with FMF reported more sleep disturbance across multiple sleep domains and higher depressive symptom scores than matched controls. The study did not find that worse sleep scores and higher depression scores moved together, and MEFV mutation status did not explain the differences. This suggests that sleep and mood burdens can be present in FMF regardless of genotype, at least in this sample. [7]

A cross-sectional pediatric study of Mediterranean diet adherence and food-choice behavior did not find a clear relationship with attack frequency or overall disease severity. Some exploratory links were reported with body weight, exertional leg pain, white blood cell count, and genotype patterns, but the design cannot show cause and effect. The same study also reported that M694V homozygosity was strongly linked to more severe disease and to colchicine resistance in this group. [8]

A large electronic-record study comparing FMF patients with non-FMF groups reported that FMF diagnosis was linked to higher odds of cirrhosis and fatty liver, while colchicine exposure was not linked to higher liver injury risk. This helps separate the possible role of the disease itself from concern about colchicine as the main driver in that dataset. Because it used health-record coding and comparisons across conditions, it cannot explain why liver risks were higher or which patients are most affected. [9]

A multicenter study of living related kidney donors who donated to recipients with FMF-related amyloidosis reported similar kidney function to matched donors, with lower rates of major heart events and new high blood pressure over a median follow-up of 4 years. This is reassuring data for donor outcomes in this specific setting, but follow-up time was limited and the study was retrospective. The results apply to screened donors, not to all family members with FMF concerns. [10]

A pediatric genetic association study found MEFV mutations were more frequent in children presenting with intussusception than in controls without intussusception. The authors proposed that FMF-related variants might contribute to risk, but the study did not show that these children had FMF or would later develop FMF. This makes the finding an early signal about a possible connection that needs follow-up. [11]

For patients, these studies mostly add understanding rather than changing what is used in everyday care. The CRP versus SAA work supports that CRP can be a solid way to follow acute inflammation in at least one setting, while PNX-14 remains a research marker since it did not track severity. The sleep and mood study highlights that quality of life burdens can be part of FMF even when genetics do not explain them, but it cannot show what causes them. The liver study helps clarify that, in one large dataset, colchicine exposure was not tied to higher liver injury risk even though FMF itself was linked to higher odds of fatty liver and cirrhosis, and the kidney donor study offers medium-term outcome data for a specific donor population. [5] [6] [7] [9] [10]

This month, mechanistic studies focused on how the pyrin inflammasome (the inflammatory pathway central to FMF) becomes overactive, and they pointed to more than one route into the same final problem. Work screening many MEFV variants separated those that seem to rely on strong CDC42 binding from those that trigger pyrin in other ways. A separate report identified a CDC42 variant in people with autoinflammation that strengthens binding to pyrin and increases inflammatory cell death and IL-1 family cytokines. Early experiments also suggested propranolol can reduce IL-1beta release after pyrin-related triggers in cells from a small number of FMF patients. [12] [13] [14]

A large cell-based functional screen tested 265 missense MEFV variants and identified previously uncharacterized variants that behaved like pathogenic changes in this assay. The researchers reported that FMF-related variants tended to bind CDC42 tightly through the pyrin B30.2 domain and that this interaction drove pyrin hyperactivation, while some non-FMF variants could hyperactivate pyrin without relying on CDC42. In plain terms, this suggests that similar FMF-like inflammation may arise through different molecular "switches," which could matter for interpreting genetic test results in the future. [12]

In patients with autoinflammation carrying a CDC42 p.T43I variant, laboratory testing showed stronger CDC42-pyrin binding and more signs of pyrin inflammasome activation, including increased pyroptosis (inflammatory cell death) and higher IL-1beta and IL-18 production. This expands the picture beyond MEFV alone by showing that changes in a pyrin-interacting partner can also push this pathway toward overactivity. The report is mechanistic and does not define how often this happens in FMF populations. [13]

An exploratory lab-and-mouse study tested propranolol (a long-used beta-blocker) and found it reduced IL-1beta release after both NLRP3 and pyrin triggers in immune cells. In monocytes from 6 FMF patients, propranolol reduced IL-1beta after activators used in the lab, and in a mouse atherosclerosis model it reduced plaque size; human safety and clinical benefit were not tested here. This positions propranolol as a research lead for inflammasome-driven inflammation, not as proven FMF treatment. [14]

For patients and caregivers, these studies mainly matter as groundwork for better genetics and future drug ideas rather than near-term changes. The MEFV variant screen helps clarify that not all genetic changes behave the same way in functional testing, which could eventually support clearer interpretation when a genetic report is uncertain. The CDC42 finding shows that genes beyond MEFV can influence the same inflammatory pathway, which may help explain some "FMF-like" cases. The propranolol work is early and based on lab systems and small cell samples, so it should be viewed as hypothesis-generating rather than evidence of benefit in people with FMF. [12] [13] [14]

This month included a single-patient report showing an unusual and severe inflammatory presentation in a pregnant person with FMF, which improved after IL-1 blockade. The case links FMF biology to eosinophilic inflammation (a marked rise in a type of white blood cell) in a way that is not yet clearly understood. It adds a real-world example that the IL-1 pathway can be a treatment target when inflammation looks different from typical FMF attacks, but it cannot show how often this occurs or whether FMF caused it. [15]

In this report, a woman with homozygous M694V developed acute eosinophilic myopericarditis and pneumonitis during pregnancy, with tamponade that required urgent drainage. After corticosteroids did not give sustained control, starting anakinra (an IL-1 blocking medicine) normalized eosinophils and CRP and allowed steroid withdrawal, with remission reported for 36 months; later she switched to canakinumab due to injection tolerance. The authors emphasized that the connection between FMF and hypereosinophilia remains uncertain. [15]

For patients, this report mainly matters as awareness that very unusual inflammatory complications can occur in individual cases and may involve pathways already known in FMF, such as IL-1. It does not change what most people with FMF should expect, because it is one person and the link to FMF was not proven. It may, however, support future research on how FMF-related inflammation can overlap with other immune patterns, especially in complex situations like pregnancy. [15]